TENX Canaccord initiated coverage of Tenax Therapeutics with a Buy rating and $35 price target. Tenax is a clinical-stage biopharma developi
TENX Canaccord initiated coverage of Tenax Therapeutics with a Buy rating and $35 price target. Tenax is a clinical-stage biopharma developing TNX-103 for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction, a large underserved market with no currently approved therapies, the analyst tells investors in a research note. The firm says the first LEVEL readout is expected at the European Society of Cardiology Congress next month. Canaccord sees "significant upside potential" to the shares, even with a "conservative" 60% probability of success to account for risks.
TENX Canaccord initiated coverage of Tenax Therapeutics with a Buy rating and $35 price target.
Tenax is a clinical-stage biopharma developing TNX-103 for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction, a large underserved market with no currently approved therapies, the analyst tells investors in a research note.
The firm says the first LEVEL readout is expected at the European Society of Cardiology Congress next month.
Canaccord sees "significant upside potential" to the shares, even with a "conservative" 60% probability of success to account for risks.